Hypochlorous acid enhances immunogenicity and uptake of allogeneic ovarian tumor cells by dendritic cells to cross-prime tumor-specific T cells

被引:66
作者
Chiang, Cheryl L-L.
Ledermann, Jonathan A.
Rad, Ariel N.
Katz, David R.
Chain, Benjamin M.
机构
[1] UCL, Dept Immunol & Mol Pathol, Div Infect & Immun, London W1T 4JF, England
[2] UCL, Dept Oncol, London, England
关键词
ovarian carcinoma; dendritic cells; hypochlorous acid; HER-2/neu; MUC-1;
D O I
10.1007/s00262-006-0127-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background: Ovarian cancer commonly relapses after remission and new strategies to target microscopic residual diseases are required. One approach is to activate tumor-specific cytotoxic T cells with dendritic cells loaded with tumor cells. In order to enhance their immunogenicity, ovarian tumor cells (SKOV3, which express two well-characterized antigens HER-2/neu and MUC-1) were killed by oxidation with hypochlorous acid (HOCl). Results: Treatment for 1 h with 60 mu M HOCl was found to induce necrosis in all SK-OV-3 cells. Oxidized, but not live, SK-OV-3 was rapidly taken up by monocyte- derived dendritic cells, and induced partial dendritic cell maturation. Dendritic cells cultured from HLA-A2 healthy volunteers were loaded with oxidized SK-OV-3 (HLA-A2(-)) and co-cultured with autologous T cells. Responding T cells were tested for specificity after a further round of antigen stimulation. In ELISPOT assays, T cells produced interferon-gamma (IFN-gamma) in response to the immunizing cellular antigen, and also to peptides coding for MUC-1 and HER-2/neu HLA-A2 restricted epitopes, demonstrating efficient cross-presentation of cell-associated antigens. In contrast, no responses were seen after priming with heat-killed or HCl-killed SK-OV-3, indicating that HOCl oxidation and not cell death/necrosis per se enhanced the immunogenicity of SK-OV-3. Finally, T cells stimulated with oxidized SK-OV-3 showed no cross-reaction to oxidized melanoma cells, nor vice versa, demonstrating that the response was tumor-type specific. Conclusions: Immunization with oxidized ovarian tumor cell lines may represent an improved therapeutic strategy to stimulate a polyclonal anti-tumor cellular immune response and hence extend remission in ovarian cancer.
引用
收藏
页码:1384 / 1395
页数:12
相关论文
共 33 条
[1]
Allison MED, 2000, EUR J IMMUNOL, V30, P2881, DOI 10.1002/1521-4141(200010)30:10<2881::AID-IMMU2881>3.0.CO
[2]
2-9
[3]
Barratt-Boyes SM, 1999, CLIN CANCER RES, V5, P1918
[4]
Necrotic but not apoptotic cell death releases heat shock proteins, which deliver a partial maturation signal to dendritic cells and activate the NF-κB pathway [J].
Basu, S ;
Binder, RJ ;
Suto, R ;
Anderson, KM ;
Srivastava, PK .
INTERNATIONAL IMMUNOLOGY, 2000, 12 (11) :1539-1546
[5]
Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells [J].
Brossart, P ;
Wirths, S ;
Stuhler, G ;
Reichardt, VL ;
Kanz, L ;
Brugger, W .
BLOOD, 2000, 96 (09) :3102-3108
[6]
Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies [J].
Brossart, P ;
Heinrich, KS ;
Stuhler, G ;
Behnke, L ;
Reichardt, VL ;
Stevanovic, S ;
Muhm, A ;
Rammensee, HG ;
Kanz, L ;
Brugger, W .
BLOOD, 1999, 93 (12) :4309-4317
[7]
Dendritic cells: a journey from laboratory to clinic [J].
Cerundolo, V ;
Hermans, IF ;
Salio, M .
NATURE IMMUNOLOGY, 2004, 5 (01) :7-10
[8]
Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells [J].
Chen, Z ;
Moyana, T ;
Saxena, A ;
Warrington, R ;
Jia, ZC ;
Xiang, J .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (04) :539-548
[9]
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines [J].
Disis, ML ;
Gooley, TA ;
Rinn, K ;
Davis, D ;
Piepkorn, M ;
Cheever, MA ;
Knutson, KL ;
Schiffman, K .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (11) :2624-2632
[10]
Cancer vaccines targeting the HER2/neu oncogenic protein [J].
Disis, ML ;
Schiffman, K .
SEMINARS IN ONCOLOGY, 2001, 28 (06) :12-20